| Methods |
Method of randomisation not clear. |
| Participants |
94 survivors of paediatric T‐cell ALL (stage nm) or low, intermediate or high risk Hodgkin lymphoma (mean age at time of study 28 years; N = 40 females and N = 54 males) treated with doxorubicin (cumulative dose average 279 mg/m2; peak dose (i.e. maximal dose received in 1 week) nm; infusion duration nm). No prior anthracycline therapy. No prior cardiac radiotherapy. Prior cardiac dysfunction before the long‐term follow‐up: N = 2 in dexrazoxane group clinical cardiomyopathy. |
| Interventions |
Dexrazoxane (ratio to doxorubicin 10:1; intravenous bolus before each doxorubicin dose) (N = 51) versus no cardioprotective intervention (N = 43). |
| Outcomes |
Heart failure (i.e. clinical cardiomyopathy and different abnormalities on echocardiography): fractional shortening < 28% in 2 dexrazoxane and 1 control participant; no results of other parameters presented. |
| Notes |
These are preliminary analyses. Median 16 years since diagnosis. Cumulative anthracycline dose per treatment group nm. Age per treatment group nm. Only a subset of participants (N = 43) had ejection fraction evaluable. |
